Simultaneous alteration of de novo and salvage pathway to the deoxynucleoside triphosphate pool by (E)-2′-Deoxy-(fluoromethylene) cytidine (FMdC) and zidovudine (AZT) results in increased radiosensitivity in vitro
Coucke, Philippe; Cottin, Eliane; Decosterd, Laurent A.
[en] Abstract
To test whether a thymidine analog zidovudine (=AZT), is able to modify the radiosensitizing effects of (E)-2'-Deoxy-(fluoromethylene)cytidine (FMdC). A human colon cancer cell line Widr was exposed for 48 hours prior to irradiation to FMdC. Zidovudine was added at various concentrations immediately before irradiation. We measured cell survival and the effect of FMdC, AZT and FMdC + AZT on deoxynucleotide triphosphate pool. FMdC results in a significant increase of radiosensitivity. The enhancement ratios (ER =surviving fraction irradiated cells/surviving fraction drug treated and irradiated cells), obtained by FMdC or AZT alone are significantly increased by the combination of both compounds. Adding FMdC to AZT yields enhancement ratios ranging from 1.25 to 2.26. FMdC reduces dATP significantly, with a corresponding increase of TTP, dCTP and dGTP. This increase of TTP, dCTP and dGTP is abolished with the addition of AZT. Adding AZT to FMdC results in a significant increase of the radiosensitizing effect of FMdC. This combination appears to reduce the reactive enhancement of TTP, dCTP and dGTP induced by FMdC while it does not affect the inhibitory effect on dATP.
Disciplines :
Oncology Hematology
Author, co-author :
Coucke, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Radiothérapie
Cottin, Eliane
Decosterd, Laurent A.
Language :
English
Title :
Simultaneous alteration of de novo and salvage pathway to the deoxynucleoside triphosphate pool by (E)-2′-Deoxy-(fluoromethylene) cytidine (FMdC) and zidovudine (AZT) results in increased radiosensitivity in vitro
Coucke PA, Decosterd LA, Li Y-X, et al. The ribonucleoside diphosphate reductase inhibitor (E)-2′-deoxy-(fluoromethylene)-cytidine as a cytotoxic radiosensitizer in vitro. Cancer Research 1999;59:5219-26.
Knol JA, Walker SC, Robertson JM, et al. Incorporation of 5-bromo-2′-deoxyuridine into colorectal liver metastases and liver in patients receiving a 7 day hepatic arterial infusion. Cancer Res 1995;55:3687-91.
Miller EM, Fowler JF, Kinsella TJ. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. I. Radiosensitization of human colon cancer cells by iododeoxyuridine. Radiat Res 1992;131:81-9.
Miller EM, Fowler JF, Kinsella TJ. Linear-quadratic analysis of radiosensitization by halogenated pyrimidines. II. Radiosensitization of human colon cancer cells by bromodeoxyuridine. Radiat Res 1992;131:90-7.
Li Y-X, Coucke PA, Paschoud N, et al. Potentiation of cytotoxicity and radiosensitization of (E)-2′-deoxy-2′-(fluoromethylene)cytidine by pentoxifylline in vitro. Int J Cancer 1999;80:155-60.
Shewach DS, Ellero J, Mancini WR. Decrease in TTP pools mediated by 5-bromo-2′-deoxyuridine exposure in a human glioblastoma cell line. Biochem Pharmacol 1992;43:1579-85.
Shewach DS, Hahn TM, Chang E, et al. Metabolism of 2′,2′- difluoro-2′-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 1994;54:3218-23.
Shewach DS, Lawrence TL. Radiosensitization of human tumor cells by gemcitabine in vitro. sem. Oncol 1995;22:68-71.
Fox RM. Changes in deoxynucleoside triphosphate pools induced by inhibitors and modulators of ribonucleotide reductase. Pharmac Ther 1985;30:31-42.
Riddler SA, Andreson RE, Mellors JW. Antiretroviral activity of stavudine (2′,3′-didehydro-3′-deoxythymidine, D4T). Antiviral Res 1995;27:189-203.
Weber G. Biochemical strategy of cancer cells and the design of chemotherapy. G. H. A. Clowes Memorial Lecture. Cancer Res 1983;43:3466-92.
Weber G, Ichikawa S, Nagai M, et al. Azidothymidine inhibition of thymidine kinase and synergistic cytotoxicity with methotrexate and 5-fluorouracil in rat hepatoma and human colon cancer cells. Cancer Communic 1990;2:129-33.
Davis MA, Tang H-Y, Maybaum J, et al. Dependence of fluoro-deoxyuridine- mediated radiosensitization on S-phase progression. Int J Radiat Biol 1995;67:509-17.
Lawrence TS, Davis MA, Maybaum J, et al. Modulation of iododeoxyuridine-mediated radiosensitization by 5-fluorouracil in human colon cancer cells. Int J Radiat Oncol Biol Phys 1992;22:499-503.
Lawrence TS, Chang EY, Hahn TM, et al. Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidine. Int J Radiat Oncol Biol Phys 1996;34:867-72.
Levin VA, Prados MR, Wara WM, et al. Radiation therapy and bromodeoxyuridine chemotherapy followed by procarbazine, lomustine and vincristine for the treatment of anaplastic gliomas. Int J Radiat Oncol Biol Phys 1995;32:75-83.
Matthews DP, Persichetti RA, Sabol JS, et al. Improved synthesis of (E)-2′-deoxy-2′-(fluoromethylene)cytidine-a potent inhibitor of ribonucleotide diphosphate reductase. Nucleosides Nucleotides Nucleic Acids 1993;12:115-23.
Snyder RD. Effect of 2′-deoxy-2′-(fluoromethylene) cytidine on the ultraviolet and x-ray sensitivity of HeLa cells. Oncol Res 1994;6:177-82.
Sun L-Q, Li Y-X, Guillou L, et al. Antitumor and radiosensitizing effects of (E)-2′-Deoxy-(fluoromethylene)cytidine, a novel inhibitor of ribonucleoside diphosphate reductase, on human colon carcinoma xenografts in nude mice. Cancer Res 1997;57:4023-8.
Sun L-Q, Li Y-X, Guillou L, et al. (E)-2′-Deoxy-(fluoromethylene) cytidine potentiates radioresponse of two human solid tumor xenografts. Cancer Res 1998;58:5411-7.
Toffoli G, Errante D, Corona G, et al. Interactions of antineoplastic chemotherapy with zidovudine pharmacokinetics in patients with HIV-related neoplasms. Cemother 1999;45:418-28.
Uhl V, Phillips TL, Ross GY, et al. Iododeoxyuridine incorporation and radiosensitization in three human tumor cell lines. Int J Radiat Oncol Biol Phys 1992;22:489-94.
Coucke PA, Cottin E, Azria D, et al. Positive interactive radiosensitization observed in vitro with the combination of two nucleoside analogs (E)-2′-deoxy-2′-(fluoromethylene) cytidine (FMdC) and iododeoxyuridine (IdUrd). Eur J Can 2004;40:1572-80.
Kanazawa J, Takahashi T, Akinaga S, et al. The relationship between the antitumor activity and ribonucleotide reductase inhibitory activity of (E)-2′-deoxy-2′-(fluoromethylene) cytidine, MDL 101,731. Anti-Cancer Drugs 1998;9:653-7.
Hannigan BM, Xu Y-Z, Chubb S, et al. Thymidine kinases: The enzymes and their clinical usefulness. Canc Biother 1993;8:189-97.
Decosterd LA, Cottin E, Chen X, et al. Simultaneous determination of deoxyribonucleoside in the presence of ribonucleoside triphosphates in human carcinoma cells by high performance liquid chromotagraphy. Annal Biochem 1999;270:59-68.
Iliakis G, Kurtzmann S. Keynote address: Application of non-hypoxic sensitizers in radiobiology and radiotherapy: Rationale and future prospects. Int J Radiat Oncol Biol Phys 1989;16:1235-41.
McCarthy JR, Matthews DP, Stemerick DM, et al. Stereospecific method to E and Z terminal fluoro olefins and its application to the synthesis of 2′-deoxy-2′-fluoromethylene nucleosides as potential inhibitors of ribonucleoside diphosphate reductase. J Am Chem Soc 1991;113:7439-40.
McGinn CJ, Shewach DS, Lawrence TS. Radiosensitizing nucleosides. JNCI 1996;88:1193-203.
Bitonti AJ, Dumont JA, Bush TL, et al. Regression of human breast tumor xenografts in response to (E)-2′-deoxy-2′-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase. Cancer Res 1994;54:1485-90.
Bitonti AJ, Bush TL, Lewis MT, et al. Response of human prostate tumor xenografts to (E)-2′-deoxy-2′-(fluoromethylene) cytidine, an inhibitor of ribonucleotide reductase. Anticancer Res 1995;15:1179-82.
Piepmeier JM, Rabidou N, Schold SC, et al. In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor. Cancer Res 1996;56:359-61.
Wright PS, Cross-Doersen D, YH'NG JPH, et al. A ribonucleotide reductase inhibitor MDL 101,731, induces apoptosis and elevates TRPM-2 mRNA levels in human prostate tumor xenografts. Exper Cell Res 1996;222:54-60.
Boothman DA, Davis TW, Sahijdak WM. Enhanced expression of thymidine kinase in human cells following ionizing radiation. Int J Radiat Oncol Biol Phys 1994;30:391-8.
Al-Nabulsi I, Takamiya Y, Voloshin Y, et al. Expression of thymidine kinase is essential to low dose radiation resistance of rat glioma cells. Cancer Res 1994;54:5614-7.
Ahluwalia GS, Gao W-Y, Mitsuya H, et al. 2′,3′-didehydro- 3′deoxythymidine: regulation of its metabolic activation by modulators of thymidine-5′-triphosphate biosynthesis. Mol Pharmacol 1996;50:160-5.
Pressaco J, Mitrovski B, Erlichman C, et al. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res 1995;55:1505-8.
Gong Y-F, Bechtold CM, Robinson BS, et al. Potentiation of the stavudine anti-human immunodeficiency virus activity by 5-fluorouracil. Antimicrob Agents Chemother 1996;40:1329.
Falcone A, Danesi R, Dargenio F, et al. Intravenous azidothymidine with fluorouracil and leucovorin: A phase I-II study in previously untreated metastatic colorectal cancer patients. J Clin Oncol 1996;14:729-36.
Klein HO, Demir G. Multi-enzyme-targeted immunotherapy. A salvage therapy protocol. Anticancer Res 1999;19:3451-8.
Posner MR, Darnowski JW, Weitberg AB, et al. High-dose intravenous zidovudine with 5-fluorouracil and leucovorin. A phase I trial. Cancer 1992;15:2929-34.
Kuo M-L, Kunugi KA, Lindstrom M-J, et al. The interaction of hydroxyurea and iododeoxyuridine on the radiosensitivity of human bladder cancer cells. Cancer Res 1995;55:2800-5.
Heinemann V, Xu Y-Z, Chubb S, et al. Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 1990;38:567-72.
Heinemann V, Schulz L, Issels RD, et al. Gemcitabine: A modulator of intracellular nucleotide and deoxynucleotide metabolism. Sem Oncol 1995;22:11-8.
Vokes EE, Stupp R, Haraf D, et al. Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil and concomittant radiotherapy for poor prognosis head and neck cancer. Semin Oncol 1995;22:47-52.
Deutsch M, Rewers AB, Redgate ES, et al. Intra-cerebral ventricular infusion of 5-iodo-2-deoxyuridine (IUDR) as a radiosensitizer in the treatment of rat glioma. Int J Radiat Biol 1990;19:85-7.
Erikson RL, Szybalski W. Molecular radiobiology of human cell lines. III. radiation-sensitizing properties of 5-iodode-oxyuridine. Cancer Res 1963;23:122-30.
Fornace AJ, Dobson PP, Kinsella TJ. Enhancement of radiation damage in cellular DNA following unifilar substitution with iododeoxyuridine. Int J Radiat Oncol Biol Phys 1990;18:873-8.
Phillips TL, Bodell WJ, Uhl V, et al. Correlation of exposure time, concentration and incorporation of IdUrd in V-79 cells with radiation response. Int J Radiat Oncol Biol Phys 1989;16:1251-5.
Copaceanu M-L, Coucke PA, Cottin E, et al. Azidothymidine (AZT) as a potential modifier of radiation response in vitro. Acta Oncol 1995;34:213-8.
